OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
26
Results
Show all
Save search
Copy query
Show results for
Unknown
(26)
Release Date
2020
(17)
2016
(4)
2022
(2)
2021
(2)
2024
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.
Not available
S-EPMC4967013
|
biostudies-literature
Cite
Proteogenomics connects somatic mutations to signalling in breast cancer.
Not available
S-EPMC5102256
|
biostudies-literature
Cite
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.
Not available
S-EPMC8077737
|
biostudies-literature
Cite
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas.
Not available
S-EPMC4884143
|
biostudies-literature
Cite
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977
|
biostudies-literature
Cite
Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries.
Not available
S-EPMC9621702
|
biostudies-literature
Cite
High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.
Not available
S-EPMC7002524
|
biostudies-literature
Cite
Genomic footprints of activated telomere maintenance mechanisms in cancer.
Not available
S-EPMC7002710
|
biostudies-literature
Cite
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer.
Not available
S-EPMC7058537
|
biostudies-literature
Cite
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.
Not available
S-EPMC7058534
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets